PP / MONOGRAPH 032 Peptide or related research compound

DSIP

Discovery history, preclinical evidence, human studies, current FDA context, and the questions that still need to be answered.

Evidence is not equivalence.

Research on a named molecule does not establish that a catalog material is the studied drug product. Identity, sequence, salt, formulation, purity, sterility, route, labeling, and indication can change the scientific and regulatory conclusion.

ORIGIN / HISTORY

When was DSIP first described?

Delta sleep-inducing peptide was characterized by Schoenenberger and Monnier in the 1970s following sleep-factor experiments in rabbits; the peptide was reported in the literature by 1977. [1]

PRECLINICAL EVIDENCE

What do animal and laboratory studies show?

Preclinical pharmacology may exist, but this registry does not treat animal or in-vitro findings as human outcomes. The literature map should be reviewed for the model, species, comparator, endpoint, and replication status. [2]

Translation limitCell and animal findings can generate mechanisms and safety signals, but they do not predict clinical benefit on their own.

CLINICAL EVIDENCE

Are there human studies?

Old, inconsistent human data; mechanism unclear. The available human evidence is limited, mixed, indirect, indication-specific, or not independently replicated; it should not be generalized to an unverified catalog material. [2][4]

Check the live study registry ↗

U.S. REGULATORY STATUS

Is DSIP FDA cleared or approved?

Drug terminology: FDA generally approves drug products; “clearance” is typically a medical-device pathway.

DSIP was among substances discussed at FDA’s July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting. Advisory-committee recommendations are non-binding and the meeting is not FDA drug approval or, by itself, final inclusion on the 503A bulks list. This page does not identify an FDA-approved product corresponding to this catalog name. [5][6][7][8]

RESEARCH OUTLOOK

Where is the scientific promise?

The scientific promise of DSIP is a hypothesis for further testing, not a demonstrated product benefit. Useful next steps would include independent replication, validated identity and purity, dose–response and toxicology work, pharmacokinetics, prespecified endpoints, and properly registered human trials before clinical conclusions are drawn. [2][4]

LIMITATIONS / PRECAUTIONS

What should professionals keep in view?

Unproven and not FDA-approved. FDA discussed emideltide/DSIP at its July 2026 advisory-committee meeting; that non-binding review was not approval or final 503A-list inclusion. [2]

Professional-use boundary

This page does not provide a diagnosis, treatment recommendation, protocol, dose, reconstitution instruction, route, or administration schedule. Any lawful program requires independent regulatory, quality, toxicology, and clinical review.

SOURCE REGISTER

References and live evidence maps

Primary papers support specific historical claims where available. PubMed and ClinicalTrials.gov links are live evidence maps, not proof that every result applies to the exact catalog material. FDA links should be rechecked because regulatory pages and product labels can change.